Navigation Links
R7128 Receives Fast Track Designation from the FDA for the Treatment of Chronic Hepatitis C Infection
Date:10/24/2007

PRINCETON, N.J., Oct. 24 /PRNewswire-FirstCall/ -- Pharmasset, Inc. (Nasdaq: VRUS) has received fast track designation from the U.S. Food and Drug Administration (FDA) for R7128 for the treatment of chronic hepatitis C virus (HCV) infection. R7128 is a prodrug of PSI-6130, an oral cytidine nucleoside analog polymerase inhibitor of HCV that is being developed through Pharmasset's collaboration with Roche. Pharmasset is currently enrolling a 28-day Phase 1 clinical trial to evaluate R7128 in combination with Pegasys(R) (pegylated interferon) plus Copegus(R) (ribavirin) in treatment-naive patients chronically infected with hepatitis C virus (HCV) genotype 1. Please see http://www.clinicaltrials.gov or e-mail clinicaltrials@pharmasset.com for more information.

Under the FDA Modernization Act of 1997, fast track designation may facilitate the development and expedite the review of a drug candidate that is intended for the treatment of a serious life-threatening condition and demonstrates the potential to address an unmet medical need for such a condition. R7128 was granted the fast track designation primarily due to the need for HCV treatments with novel mechanisms of action, oral administration, different resistance profiles and improved safety and efficacy over the existing standard of care for both treatment-naive and treatment-experienced patients.

"The FDA's fast track designation for R7128 acknowledges the urgent need for new HCV drugs," stated Dr. Michelle Berrey, Pharmasset's Vice President, Clinical Development & Chief Medical Officer. "Currently, there are no HCV polymerase inhibitors approved for the treatment of chronic HCV infection. We cont
'/>"/>

SOURCE Pharmasset, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Sirion Therapeutics Receives Orphan Drug Designation for Ophthalmic Drug to Treat Viral Eye Infection
2. Protalix BioTherapeutics, Inc. Receives Approval from the FDA to Initiate a Phase III Clinical Trial of prGCD
3. DUSA Pharmaceuticals Receives Orphan Drug Desi gnation for Levulan PDT to Treat Esophage al Dysplasia
4. Gloucester Pharmaceuticals Receives Fast Track Designation for Romidepsin in Peripheral T-Cell Lymphoma
5. Based on Up to 6 Years of Follow-Up, Biovest Announces Favorable Interim Blinded Data for Fast-Tracked Pivotal Phase 3 Clinical Trial of BiovaxID Anti-Cancer Vaccine for Non-Hodgkins Lymphoma
6. Accentia Biopharmaceuticals Announces Favorable Interim Blinded Data on SinuNase in Its Fast-Tracked Pivotal Phase 3 Clinical Trial for Chronic Sinusitis
7. Stanford Researchers Track Human Stem Cells Transplanted Into Rat Brain
8. Pixantrone Granted Fast Track Designation by FDA for Relapsed Indolent NHL Patients
9. Staphylococcus aureus vaccine development on track ? safe and immunogenic in Phase I clinicaltrials
10. Allos Therapeutics PDX Granted Orphan Medicinal Product Designation by the European Commission
11. Point of Care Strep Tests Speed Treatment, Lower Costs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... NEW YORK , Jan. 15, 2014 ... research report is available in its catalogue: ... - India Drug Forecast and Market Analysis ... PharmaPoint: Atopic Dermatitis - India ...
(Date:1/15/2014)... Jan. 15, 2014  A novel wearable injector slightly larger than ... for patients to self-inject prescription drugs in the large doses ... blood diseases, autoimmune deficiencies, and genetic disorders.  ... $220B by 2018, according to analysts.   Many of these drugs ...
(Date:1/14/2014)... Healthcare Services, Inc. ("DHS"), a portfolio company of GMH Ventures ... Equipment, Inc. ("Progressive") of Clarion, PA ... not disclosed. Progressive is a full service ... sleep, mobility, and respiratory products to customers in the western ...
Breaking Medicine Technology:PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 2Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 3
... Halozyme Therapeutics, Inc. (Nasdaq: HALO ) today ... HYLENEX manufacturing and has identified a corrective action plan ... Halozyme and Baxter are finalizing the materials for a ... seek concurrence with the reintroduction strategy. During several meetings ...
... LONDON, Aug. 31 Following a recent analysis ... Sullivan presented Lodox Systems (Pty) Ltd (Lodox) with ... Leadership Award".  Statscan, Lodox,s digital x-ray product, stunned ... diagnostic, whole-body x-ray pictures in just 13 seconds. ...
Cached Medicine Technology:Halozyme Provides HYLENEX® Product Reintroduction Update 2Halozyme Provides HYLENEX® Product Reintroduction Update 3Frost & Sullivan Applauds the Lodox Statscan Critical Imaging System for Outperforming All Competing Products 2Frost & Sullivan Applauds the Lodox Statscan Critical Imaging System for Outperforming All Competing Products 3Frost & Sullivan Applauds the Lodox Statscan Critical Imaging System for Outperforming All Competing Products 4
(Date:4/17/2014)... vaccine brands for children may not be the most ... factors when choosing vaccines, driving the market toward what ... new study by University of Illinois researchers. , "The ... numerous factors," says Sheldon H. Jacobson, a co-author of ... of mathematics at the U. of I. "In an ...
(Date:4/17/2014)... Diego School of Medicine report that older women, plucky ... loss are more likely to be compassionate toward strangers ... in this month,s issue of the International Journal ... associated with better health and well-being as we age, ... the outcomes of individuals whose deficits in compassion put ...
(Date:4/17/2014)... Pediatrician-in-Chief Jon McCullers, MD, was recently invited to ... Nature Reviews Microbiology , one of the ... world-renowned infectious disease specialist, and chair of the ... Health Science Center, analyzed the epidemiology and microbiology ... pandemics, as well as more recent 2009 novel ...
(Date:4/17/2014)... who treat patients with a severe and progressive ... agonizing treatment decision. , The drug sirolimus can ... shortness of breath. But some patients eventually may ... fatal complications following transplantation. , "It,s a terrible ... of Loyola University Medical Center,s LAM Clinic and ...
(Date:4/17/2014)... IL, April 17, 2014-- Colic affects about one in ... for numerous pediatric visits during the first several months ... colic symptoms was showing promise; however, the April 1, ... (BMJ2014;348:g2107; Sung, Valerie) reported on a study, "Probiotics and ... L reuteri for infant colic did ...
Breaking Medicine News(10 mins):Health News:Study recalculates costs of combination vaccines 2Health News:The ilk of human kindness 2Health News:Patients with rare lung disease face agonizing treatment dilemma 2Health News:Patients with rare lung disease face agonizing treatment dilemma 3Health News:New study says probiotic use for infant colic is not effective in reducing symptoms 2
... Saving Benefit Faces Eventual Elimination Without Relief , ... of President Obama,s pledge not to raise taxes on the ... outside of the normal legislative process -- adopting provisions approved ... the use of flexible spending accounts (FSAs) in order to ...
... from a new virtual reality training programme created at ... have been working with researchers in the School of ... scenarios that test expert players, perceptual skills. Lead ... Senior Lecturer in Visual Perception who has previously collaborated ...
... to educate, inform, and empower the people of Chicago, ... its 25-minute live call-in show, "Community Health," on ... at 6:00 PM on Channel 21. , ... Health Clinics with Erin Buckley, FNP-C, Certified Family Nurse ...
... Oct. 14 Peter Sheldon, Vice President of Operations ... commercial cleaning businesses, will be a featured speaker at ... to be held on October 14-15 at The Fairmont ... is "Be the Best in Your Business with Best ...
... 15, 2009 marks the 35th anniversary of the founding of ... McDonald Houses in 52 countries and regions throughout the world, ... the Philadelphia House,s two locations (on Chestnut Street, and at ... McDonald House of Southern New Jersey, the world,s 51st House, ...
... ... a few years ago, today it seems "Natural" is the new buzz word in retail, ... Buster was recently featured on an episode of The Dr. Oz Show in a segment ... ...
Cached Medicine News:Health News:Fight to Preserve Flexible Spending Accounts Moves to the House of Representatives 2Health News:Fight to Preserve Flexible Spending Accounts Moves to the House of Representatives 3Health News:Increased success a 'virtual' certainty for rugby players 2Health News:Retail Health Clinics - The Real Story 2Health News:Coverall Executive Peter Sheldon To Be Featured Speaker at PRSM Mid-Year Conference 2Health News:Philadelphia-Born Ronald McDonald House(R) Program Celebrates 35 Years 2Health News:Philadelphia-Born Ronald McDonald House(R) Program Celebrates 35 Years 3Health News:Sinus Buster Paves the Way for Natural OTC Products and Mainstream Success 2
Lambotte periosteal elevators....
Modified Freer periosteal elevator, #163, slight curve, 21 cm....
Williger periosteal elevator, 6 1/4", sharp, 5 mm wide....
Alley periosteal elevator, extra long, 21 cm, 8-1/4"....
Medicine Products: